rna
interfer
promis
strategi
treatment
huntington
diseas
hd
specif
decreas
express
mutant
huntingtin
protein
htt
howev
sirna
cross
bloodbrain
barrier
therefor
deliveri
brain
limit
direct
cn
deliveri
noninvas
deliveri
sirna
bloodbrain
barrier
bbb
would
signific
advantag
translat
therapi
hd
patient
focus
ultrasound
fu
combin
intravascular
deliveri
microbubbl
contrast
agent
use
local
transient
disrupt
bbb
right
striatum
adult
rat
hr
follow
treatment
sirna
right
treat
left
control
striatum
dissect
analyz
htt
mrna
level
demonstr
fu
noninvas
deliv
sirnahtt
directli
striatum
lead
signific
reduct
htt
express
dose
depend
manner
furthermor
show
reduct
htt
sirnahtt
greater
extent
bbb
disrupt
increas
studi
demonstr
sirna
treatment
knockdown
mutant
htt
feasibl
without
surgic
intervent
previous
requir
direct
deliveri
brain
focus
ultrasound
sirna
drug
deliveri
huntington
diseas
bloodbrain
barrier
huntington
diseas
hd
progress
neurodegen
diseas
caus
expans
cag
repeat
huntingtin
htt
gene
mutat
caus
gain
function
htt
protein
result
neuron
dysfunct
cell
death
lead
involuntari
movement
cognit
dysfunct
behavior
chang
characterist
hd
although
diseas
monogen
etiolog
known
current
treatment
condit
mous
model
hd
observ
silenc
mutant
htt
transgen
use
tetracyclin
revers
halt
progress
diseas
research
indic
therapeut
approach
reduc
level
htt
might
effect
strategi
treat
hd
sinc
shown
short
hairpin
rna
shrna
deliv
viral
vector
lead
decreas
htt
protein
associ
patholog
howev
shrna
toxic
integr
genom
similar
approach
use
small
interf
rna
sirna
suppress
express
htt
gene
conjug
bioactiv
sirna
cholesterol
known
improv
cellular
uptak
sirna
vivo
deliveri
cholesterolconjug
cc
sirna
htt
revers
patholog
hd
mous
model
studi
ccsirnahtt
inject
directli
striatum
found
decreas
htt
protein
express
improv
motor
function
increas
neuron
surviv
recent
studi
nonhuman
primat
unconjug
sirna
target
htt
administ
continu
infus
putamen
effect
reduc
htt
express
throughout
striatum
sirna
administ
cerebr
ventricl
brain
parenchyma
shown
safe
effect
mice
nonhuman
primat
howev
system
deliveri
sirna
abl
pass
bloodbrain
barrier
bbb
would
use
treat
hd
sinc
invas
surgic
intervent
could
avoid
studi
investig
potenti
mriguid
focus
ultrasound
mrigfu
noninvas
deliv
ccsirnahtt
directli
striatum
advanc
fu
technolog
use
transient
increas
permeabl
bbb
allow
agent
cross
blood
stream
brain
fu
appli
concentr
acoust
energi
focal
spot
measur
millimet
diamet
microbubbl
contrast
agent
administ
system
fu
appli
transcrani
target
locat
circul
microbubbl
begin
oscil
lead
mechan
chang
blood
vessel
wall
transient
increas
permeabl
bbb
previou
work
shown
transient
chang
bbb
permeabl
induc
fu
permit
entri
chemotherapeut
therapeut
antibodi
target
area
brain
perform
proof
principl
studi
address
whether
mrigfu
could
effect
deliveri
method
sirna
striatum
patient
hd
demonstr
striatum
accur
target
mrigfu
rat
also
show
sirna
biolog
activ
vivo
deliveri
mrigfu
administr
ccsirnahtt
led
signific
reduct
htt
express
dose
depend
manner
reduct
observ
use
control
sirna
furthermor
demonstr
htt
knockdown
correl
amount
contrast
enhanc
observ
weight
mr
imag
togeth
result
suggest
mrigfu
effect
tool
noninvas
deliveri
sirna
investig
treatment
hd
singlestrand
rna
synthes
alnylam
pharmaceut
character
esim
anion
exchang
hplc
singlestrand
rna
synthes
deoxythymidin
dt
overhang
includ
substitut
subset
intern
nucleotid
phosphorothio
linkag
provid
stabil
nucleas
gener
sirna
rna
singl
strand
equimolar
amount
complementari
sens
antisens
strand
anneal
sequenc
sirnahtt
sirnaluc
previous
publish
wistar
rat
receiv
charl
river
laboratori
sherbrook
qc
canada
experiment
procedur
approv
sunnybrook
research
institut
anim
care
use
committe
conform
guidelin
set
anim
research
act
ontario
canadian
council
anim
care
anim
anesthet
ketamin
mgkg
xylazin
mgkg
depilatori
cream
use
remov
hair
head
anim
place
supin
custombuilt
fu
posit
system
head
coupl
degass
water
bag
entir
system
place
mr
scanner
signia
ge
healthcar
milwauke
wi
baselin
te
ms
ms
ms
ms
imag
acquir
imag
combin
stereotax
atla
use
choos
squar
precis
target
point
mm
space
right
striatum
figur
anim
place
group
control
rat
receiv
intraven
salin
inject
vehicl
control
receiv
intraven
inject
ccsirnaluc
treatment
rat
receiv
intraven
inject
ccsirnahtt
per
dose
carotid
rat
receiv
intracarotid
inject
ccsirnahtt
case
ccsirnahtt
inject
tail
vein
cathet
intracarotid
cathet
follow
inject
microbubbl
contrast
agent
mlkg
lantheu
medic
n
billerica
immedi
prior
sonic
sonic
complet
use
khz
transduc
mpa
estim
situ
pressur
ms
burst
hz
puls
repetit
frequenc
total
exposur
durat
follow
sonic
gadolinium
contrast
agent
mlkg
omniscan
ge
healthcar
milwauke
wi
inject
tail
vein
follow
ml
salin
flush
contrast
enhanc
imag
use
confirm
bbb
open
fu
anim
maintain
anesthet
sonic
second
time
use
paramet
hr
follow
first
sonic
second
inject
sirna
administ
prior
second
sonic
anim
sacrif
hr
second
sonic
sacrific
left
right
striatum
dissect
brain
snap
frozen
dri
ice
quantigen
assay
affymetrix
santa
clara
ca
use
quantifi
mrna
level
tissu
sampl
lysat
accord
manufactur
instruct
htt
mrna
level
normal
gapdh
mrna
level
normal
control
anim
imag
combin
rat
stereotax
atla
use
precis
target
mm
squar
region
striatum
right
hemispher
figur
b
sirna
inject
tail
vein
immedi
prior
sonic
follow
fu
bbb
open
confirm
inject
mr
contrast
agent
tail
vein
acquir
contrastenhanc
imag
figur
postson
imag
demonstr
bbb
disrupt
target
striatum
confirm
target
accur
sirna
deliv
intend
region
cholesterol
conjug
shown
improv
cellular
uptak
sirna
hepatocyt
neuron
therefor
synthes
cholesterol
conjug
cc
sirna
silenc
htt
ccsirnahtt
luciferas
ccsirnaluc
latter
use
control
ccsirna
deliv
right
striatum
brain
separ
sonic
bdna
analysi
perform
hr
later
show
ccsirnahtt
significantli
decreas
htt
bdna
p
figur
wherea
ccsirnaluc
effect
htt
bdna
level
result
confirm
specif
ccsirnahtt
htt
mrna
furthermor
result
clearli
demonstr
mrigfu
effect
method
deliveri
bioactiv
sirna
striatum
deliv
variou
dose
sirna
determin
achiev
level
htt
reduct
vivo
immedi
prior
bbb
disrupt
variou
concentr
ccsirnahtt
mgkg
administ
tail
vein
anim
surviv
hr
bdna
analysi
show
dose
depend
correl
decreas
htt
bdna
concentr
ccsirnahtt
dose
mgkg
figur
mgkg
level
htt
decreas
p
larger
dose
sirna
mgkg
administ
decreas
htt
level
significantli
differ
mgkg
figur
suggest
maxim
reduct
htt
use
system
howev
suggest
modest
reduct
htt
function
lead
substanti
improv
diseas
symptom
examin
whether
could
increas
amount
ccsirnahtt
enter
brain
first
pass
administ
sirna
carotid
arteri
anim
sirna
administ
carotid
simultan
inject
microbubbl
tail
vein
result
show
carotid
deliveri
increas
htt
knockdown
compar
deliveri
sirna
tail
vein
data
shown
next
compar
amount
htt
knockdown
extent
bbb
open
determin
measur
intens
enhanc
right
sonic
striatum
left
nonson
striatum
posttreat
mr
imag
rel
enhanc
rang
tabl
plot
enhanc
amount
htt
mrna
express
percentag
control
found
enhanc
htt
knockdown
posit
correl
extent
htt
knockdown
found
posit
correl
extent
enhanc
r
figur
data
separ
group
enhanc
enhanc
posit
relationship
enhanc
htt
knockdown
confirm
figur
reduc
level
mutant
htt
patient
hd
repres
ultim
direct
approach
treatment
deliveri
sirna
plausibl
option
reduc
htt
express
studi
use
sirna
anim
model
hd
shown
improv
diseas
outcom
one
major
concern
treatment
deliveri
sirna
brain
without
use
toxic
transfect
agent
surgeri
studi
demonstr
mrigfu
noninvas
effect
deliv
sirna
striatum
lead
decreas
htt
gene
express
demonstr
signific
decreas
htt
express
follow
deliveri
ccsirnahtt
striatum
mrigfu
observ
decreas
htt
mrna
similar
decreas
observ
studi
typic
sirna
partial
reduc
express
endogen
neural
target
sometim
littl
howev
modest
reduct
htt
mrna
shown
provid
therapeut
benefit
anim
model
huntington
diseas
rnai
studi
report
todat
use
direct
viral
deliveri
shrna
cn
anim
model
huntington
diseas
htt
mrna
suppress
approxim
greater
result
meaning
normal
neuropatholog
behavior
detail
ad
discuss
observ
dosedepend
relationship
ccsirnahtt
concentr
reduct
htt
dna
beyond
mgkg
may
attribut
two
differ
mechan
first
natur
bbb
disrupt
mrigfu
transient
thu
possibl
bbb
repair
quickli
enough
sirna
enter
brain
result
show
extent
htt
knockdown
relat
amount
bbb
disrupt
suggest
signific
bbb
disrupt
requir
ccsirna
enter
striatum
howev
similar
studi
increas
bbb
permeabl
persist
hour
halflif
ccsirna
circul
expand
min
suggest
adequ
time
sirna
cross
brain
second
possibl
limit
due
molecular
target
abil
silenc
complet
regardless
mechan
appar
limit
reduct
htt
may
actual
ideal
treatment
clinic
set
optim
sirna
treatment
hd
would
specif
target
mutant
form
htt
prove
challeng
recent
result
suggest
specif
mutant
htt
wildtyp
htt
achiev
vitro
though
rel
high
nanomolar
concentr
contrast
picomolar
potenc
typic
achiev
sirna
vitro
reason
group
other
gener
sirna
result
decreas
express
mutant
wildtyp
form
htt
suppress
mutant
htt
would
fine
balanc
suppress
wildtyp
htt
known
import
neuron
develop
surviv
base
previou
literatur
hypothes
reduct
wildtyp
htt
shown
experi
would
well
toler
long
term
howev
investig
would
necessari
ensur
treatment
would
suitabl
clinic
applic
evid
suggest
uptak
sirna
striatum
correl
rout
deliveri
contrari
initi
belief
sirna
would
avail
move
bbb
first
pass
vasculatur
paracellular
space
greatest
deliveri
sirna
carotid
arteri
lead
significantli
htt
knockdown
sirna
deliv
tail
vein
howev
find
correl
amount
contrast
enhanc
posttreat
imag
htt
knockdown
suggest
success
sirna
directli
relat
much
bbb
disrupt
achiev
sever
rout
passag
bbb
describ
like
ccsirna
move
paracellularli
widen
tight
junction
brain
howev
passag
via
transcellular
mechan
peak
approxim
hr
sonic
also
possibl
due
extend
halflif
ccsirna
clear
advantag
use
mrigfu
deliveri
sirna
brain
hd
patient
first
major
limit
hd
research
thu
far
adequ
distribut
compound
brain
area
suffici
quantiti
observ
meaning
effect
use
mrigfu
demonstr
deliv
sirna
small
region
striatum
mrna
analysi
clearli
demonstr
suffici
quantiti
sirna
deliv
brain
fu
impact
function
sirna
futur
combin
ccsirnahtt
microbubbl
may
improv
drug
avail
tissu
similar
previou
studi
bbb
disrupt
fu
repeatedli
shown
occur
minor
red
blood
cell
extravas
without
impact
efficaci
deliv
drug
secondli
effect
sirna
vivo
persist
long
week
howev
treatment
hd
requir
intervent
mani
year
mrigfu
provid
uniqu
treatment
option
regard
therapi
noninvas
repeat
safe
multipl
time
system
administr
unmodifi
sirna
shown
stimul
innat
immun
system
lead
cytokin
product
extent
immunolog
pathway
activ
depend
upon
sequenc
structur
qualiti
sirna
modif
use
sirna
demonstr
elimin
immun
stimul
sirna
class
without
compromis
silenc
activ
use
sirna
similar
chemic
modif
difiglia
colleagu
evalu
reactiv
microglia
astrocyt
determin
measur
inflammatori
respons
follow
inject
sirna
striatum
futur
studi
focu
comprehens
analysi
cn
immunostimul
sirna
administr
use
mrigfu
nonetheless
current
studi
suggest
sirna
administr
use
mrigfu
repres
promis
therapeut
approach
warrant
investig
treatment
cn
disord
hd
right
striatum
red
x
target
regist
stereotax
atla
imag
imag
rat
brain
b
bbb
open
confirm
use
contrastenhanc
imag
c
hyperintens
region
imag
indic
presenc
contrast
agent
right
striatum
follow
effect
bbb
disrupt
cholesterol
conjug
cc
sirna
gener
silenc
htt
ccsirnahtt
luciferas
ccsirnaluc
control
bdna
analysi
perform
hr
later
show
cchtt
significantli
decreas
htt
bdna
p
wherea
ccluc
effect
htt
level
vivo
data
repres
anim
per
group
variou
dose
mgkg
ccsirnahtt
administ
tail
vein
anim
surviv
hr
analysi
show
dose
depend
correl
decreas
htt
concentr
ccsirnahtt
dose
mgkg
mgkg
level
htt
decreas
p
larger
dose
sirna
administ
decreas
htt
level
significantli
differ
mgkg
data
repres
anim
per
group
enhanc
measur
contrast
enhanc
imag
plot
amount
htt
express
control
posit
correl
observ
r
indic
greater
htt
knockdown
found
anim
greater
level
enhanc
observ
b
data
bin
group
enhanc
enhanc
dose
ccsirnahtt
knockdown
observ
enhanc
greater
